Evidence map›Paper›PMID 33621147›Full record

ReviewSeminars in ophthalmology2021

Potential of Application of Iron Chelating Agents in Ophthalmic Diseases.

Alireza Ghaffarieh, Joseph B Ciolino

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Research progress of iron metabolism in retinal diseases.Advances in ophthalmology practice and research
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Alireza GhaffariehOphthalmology, Cornea, External Disease & Refractive Surgery Fellow, Massachusetts Eye and Ear Infirmary, Harvard University, USA.
Joseph B CiolinoOphthalmology, Associate Professor of Ophthalmology, Harvard Medical School Mass. Eye and Ear/Schepens Eye Research Institute, USA.
Harvard University · USSmith-Kettlewell Eye Research Institute · US

Funding

Antibiotic eluting contact lenses for the treatment of bacterial keratitisR01EY026640 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI CIOLINO, JOSEPH B. · 2017 to 2020
$2.0M
NEI NIH HHS R01 EY026640
6 · The paper itself

Abstract

The investigations discussed in this review indicate that iron may exacerbate different eye diseases. Therefore, it is plausible that reducing cellular or body iron stores could influence disease pathogenesis, so it is logical to consider the iron chelators' potential protective role in the various ophthalmic diseases in the form of topical eye drops or slow releasing injectable compounds as an adjuvant treatment.

Indexed as

Eye DiseasesMacular DegenerationHumansIronIron Chelating AgentsOphthalmic SolutionsIronIron Chelating AgentsOphthalmic Solutionsage-related macular degeneration (AMD)Iron chelating agentslens damagenitrogen mustard gas eye injuryocular infection

Identifiers

PMID33621147
PMCPMC8554538
OpenAlexW3132812326

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.